New York State Teachers Retirement System Has $3.67 Million Stock Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

New York State Teachers Retirement System cut its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 3.8% in the 4th quarter, HoldingsChannel.com reports. The firm owned 84,163 shares of the life sciences company’s stock after selling 3,321 shares during the quarter. New York State Teachers Retirement System’s holdings in Integra LifeSciences were worth $3,665,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. Itau Unibanco Holding S.A. lifted its position in shares of Integra LifeSciences by 469.5% in the second quarter. Itau Unibanco Holding S.A. now owns 746 shares of the life sciences company’s stock valued at $31,000 after buying an additional 615 shares during the last quarter. Gladius Capital Management LP acquired a new stake in shares of Integra LifeSciences in the third quarter valued at approximately $47,000. Covestor Ltd lifted its position in shares of Integra LifeSciences by 82.5% in the third quarter. Covestor Ltd now owns 2,037 shares of the life sciences company’s stock valued at $78,000 after buying an additional 921 shares during the last quarter. Coppell Advisory Solutions LLC acquired a new stake in shares of Integra LifeSciences in the second quarter valued at approximately $84,000. Finally, Captrust Financial Advisors lifted its position in shares of Integra LifeSciences by 95.0% in the first quarter. Captrust Financial Advisors now owns 2,003 shares of the life sciences company’s stock valued at $129,000 after buying an additional 976 shares during the last quarter. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Price Performance

Integra LifeSciences stock opened at $32.80 on Monday. The stock’s fifty day moving average price is $37.84 and its two-hundred day moving average price is $39.33. Integra LifeSciences Holdings Co. has a one year low of $32.50 and a one year high of $59.33. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.45 and a quick ratio of 2.18. The firm has a market cap of $2.58 billion, a PE ratio of 39.52, a price-to-earnings-growth ratio of 0.99 and a beta of 1.12.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Wednesday, February 28th. The life sciences company reported $0.89 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The company had revenue of $397.00 million for the quarter, compared to the consensus estimate of $399.30 million. During the same quarter last year, the business earned $0.94 EPS. Integra LifeSciences’s revenue was down .3% on a year-over-year basis. As a group, research analysts expect that Integra LifeSciences Holdings Co. will post 3.19 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

IART has been the subject of a number of recent analyst reports. JMP Securities cut their price objective on Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating for the company in a research report on Thursday, February 29th. Truist Financial cut their price objective on Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a research report on Friday, March 1st. StockNews.com cut Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Friday, April 5th. Finally, Citigroup raised Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price target for the company in a report on Wednesday, April 3rd. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $44.89.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.